Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0NE5B
|
|||
Drug Name |
Rintatolimid
|
|||
Synonyms |
Ampligen; Atvogen; Poly I:Poly C12U; POLYI-POLYC12U; Poly(I).poly(c12,U); Mismatched double-stranded RNA; Poly I-Poly C (C12,U); (rI(n).r(C(12)U)n); DRG-0001; Poly(inosinic acid) poly(cytidylic(12), uridylic)acid; 38640-92-5; 5'-Inosinic acid, homopolymer, complex with 5'-cytidylic acid polymer with 5'-uridylic acid (1:1); Poly(I)-Poly(C12U); Rintatolimod [USAN:INN]; UNII-94325AJ25N; SCHEMBL27306; AC1L1Z15; DTXSID50191952; 94325AJ25N; LS-174734; C10H13N4O8P.C9H13N2O9P.C9H14N3O8P; 1308845-87-5; 1221495-86-8
Click to Show/Hide
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1/2 | [1] | |
Chronic fatigue syndrome [ICD-11: 8E49; ICD-10: G93.3] | Application submitted | [2] | ||
Company |
Hemispherx Biopharma Philadelphia, PA
|
|||
Structure |
Download2D MOL |
|||
Formula |
C28H40N9O25P3
|
|||
Canonical SMILES |
C1=CN(C(=O)N=C1N)C2C(C(C(O2)COP(=O)(O)O)O)O.C1=CN(C(=O)NC1=O)C2C(C(C(O2)COP(=O)(O)O)O)O.C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)COP(=O)(O)O)O)O
|
|||
InChI |
1S/C10H13N4O8P.C9H14N3O8P.C9H13N2O9P/c15-6-4(1-21-23(18,19)20)22-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)17;10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(20-8)3-19-21(16,17)18;12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(20-8)3-19-21(16,17)18/h2-4,6-7,10,15-16H,1H2,(H,11,12,17)(H2,18,19,20);1-2,4,6-8,13-14H,3H2,(H2,10,11,15)(H2,16,17,18);1-2,4,6-8,13-14H,3H2,(H,10,12,15)(H2,16,17,18)/t4-,6-,7-,10-;2*4-,6-,7-,8-/m111/s1
|
|||
InChIKey |
KNUXHTWUIVMBBY-JRJYXWDASA-N
|
|||
CAS Number |
CAS 38640-92-5
|
|||
PubChem Compound ID |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.